CDT Equity (NASDAQ:CDT) Posts Quarterly Earnings Results

CDT Equity (NASDAQ:CDT) announced its quarterly earnings results on Wednesday. The company reported ($5.56) EPS for the quarter, FiscalAI reports.

CDT Equity Stock Up 0.3%

Shares of CDT Equity stock traded up $0.00 on Wednesday, reaching $0.35. The stock had a trading volume of 171,496 shares, compared to its average volume of 3,318,668. The stock has a market capitalization of $1.71 million, a P/E ratio of -0.00 and a beta of 1.49. The company has a 50 day moving average price of $0.99 and a 200 day moving average price of $12.85. CDT Equity has a 1 year low of $0.34 and a 1 year high of $461.54.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. Wall Street Zen cut shares of CDT Equity to a “strong sell” rating in a report on Saturday, June 27th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CDT Equity in a research report on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

About CDT Equity

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.